International Drug Development Pipeline Strengthened by New Partnership Between Canada's Centre for Drug Research and Development and Japan's University of Tokyo
(firmenpresse) - TOKYO, JAPAN and VANCOUVER, CANADA -- (Marketwire) -- 10/04/11 -- Against the backdrop of the 2011 BioJapan Conference underway in Tokyo, The Centre for Drug Research and Development (CDRD) and TODAI TLO Ltd., a technology transfer organization for the University of Tokyo, announced the signing of an International Affiliation Agreement facilitating joint research projects between the two organizations.
"We are pleased to be sharing knowledge and resources across the Pacific, and to be building this bridge between CDRD and the University of Tokyo, home to one of Japan's pre-eminent medical research institutes and a top-ranking university by global standards," commented Karimah Es Sabar, CDRD's Senior Vice President of Business and Strategic Affairs. "Recognizing the global nature of the life sciences industry, CDRD is strongly committed to establishing and collaborating with a network of international affiliates representing the world's top research institutions," she said.
TODAI TLO, which manages all intellectual property from the University of Tokyo, received 648 invention disclosures last year. Health research discoveries made at the University will now have an opportunity to be advanced towards commercialization via CDRD's specialized drug development infrastructure and professional project management, and scientific and business expertise.
President and CEO of TODAI, Takafumi Yamamoto noted, "In general, most of the inventions disclosed at the University are pre-commercial technologies that require much further development. We believe that this affiliation agreement with CDRD will bring many benefits to the university and researchers to address this gap in the commercialization path."
One major purpose of the University of Tokyo is the technology transfer of intellectual assets from their research groups in the service of society. In this context, TODAI TLO is commissioned to manage and deal with all the university's intellectual assets, and to promote their dissemination into society. It assesses the technologies developed by researchers, efficiently secures the technology rights, and then makes the technologies available to the world.
This goal is well complemented by CDRD's mission of improving people's health worldwide by assisting in the advancement of promising drug-related discoveries from academia to a commercially attractive stage, and building a collaborative research infrastructure to increase research and development capacity both in Canada and internationally.
About CDRD
The Centre for Drug Research and Development (CDRD), a national Centre of Excellence for Commercialization and Research (CECR), is a not-for-profit public-private organization that provides drug development expertise and infrastructure to enable researchers from leading academic and health research institutions to advance promising, early-stage drug candidates. CDRD has supported some 95 research projects generated from its network of 20+ affiliated research institutions across Canada. These institutions represent billions invested in health-related research every year, and CDRD plays a pivotal role in translating that research into commercial products and economic returns including new jobs for British Columbia and Canada. For additional information, visit .
Contacts:
The Centre for Drug Research and Development
Barry Gee
Director, Communications
(604) 221-7750 x 223
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.10.2011 - 03:32 Uhr
Sprache: Deutsch
News-ID 72897
Anzahl Zeichen: 0
contact information:
Town:
TOKYO, JAPAN and VANCOUVER, CANADA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"International Drug Development Pipeline Strengthened by New Partnership Between Canada's Centre for Drug Research and Development and Japan's University of Tokyo"
steht unter der journalistisch-redaktionellen Verantwortung von
The Centre for Drug Research and Development (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
